HIFU FOR
PROSTATE CANCER
Transrectal HIFU ablates prostate cancer with surgical precision — targeting either the cancer-bearing zone alone (focal therapy) or the entire prostate gland (whole-gland) — with lower rates of urinary incontinence and erectile dysfunction than radical prostatectomy.
analyticsAt a Glance
- check_circleCE-marked in Europe; widely used in China as a curative-intent treatment for localised prostate cancer
- check_circleFocal HIFU targets only the cancer zone — preserving uninvolved prostate, neurovascular bundles, and continence mechanism
- check_circle10-year biochemical recurrence-free survival of 70–80% for whole-gland HIFU in low-intermediate risk disease
- check_circleAccessible at specialist urology centres in China via CancerFax — at significantly lower cost than Western HIFU programmes
Why HIFU Has a Role in Prostate Cancer Treatment
Localised prostate cancer treatment has always faced a difficult trade-off: radical prostatectomy and radiotherapy achieve excellent cancer control but carry 20–40% rates of permanent urinary incontinence and erectile dysfunction that significantly impair quality of life. HIFU reframes this trade-off — delivering targeted ablation of the prostate transrectally, under spinal or general anaesthesia, in 1–3 hours, with recovery measured in days rather than weeks.
“For a man with MRI-visible, biopsy-confirmed localised prostate cancer who wants active treatment but fears the quality-of-life impact of surgery — focal HIFU offers a third path that wasn't available 15 years ago.”
Focal HIFU: Treating Only the Cancer
Multiparametric MRI and fusion-targeted biopsy have made it possible to precisely locate cancer within the prostate. Focal HIFU ablates only the MRI-visible, biopsy-confirmed cancer-bearing zone — typically a hemi-ablation (one lobe) or quadrant ablation — leaving uninvolved prostate, neurovascular bundles, and the external urethral sphincter intact.
Whole-Gland HIFU: Complete Prostate Ablation
Whole-gland HIFU treats the entire prostate from the bladder neck to the apex, destroying all prostatic tissue. It is appropriate for unifocal or multifocal intermediate-risk disease where cancer cannot be reliably localized to one zone — and for patients who prefer comprehensive treatment over the surveillance requirement of focal therapy.
Key Clinical Numbers
Published data from European and Chinese HIFU prostate registries document the following outcome benchmarks.
- 70–80%10-year biochemical recurrence-free survival (whole-gland, low-intermediate risk)Reported from Ablatherm and Sonablate registry data — comparable to external beam radiotherapy in similar risk groups.
- 2–5%Pad-free urinary incontinence rate (focal HIFU)Significantly lower than radical prostatectomy (15–25% at 1 year); whole-gland HIFU incontinence rate ~5–10%.
- 65–75%Erectile function preservation (focal HIFU, nerve-sparing zone)For patients with preserved function pre-treatment; substantially higher than radical prostatectomy bilateral nerve-sparing rates.
- 1–3 hrsProcedure durationWhole-gland HIFU takes 2–3 hours; hemi-ablation focal HIFU typically 1–2 hours under spinal or general anaesthesia.
Focal HIFU vs Whole-Gland HIFU: Decision Guide
The choice between focal and whole-gland HIFU depends on cancer distribution, risk category, PSA, and patient priorities around quality-of-life outcomes.
| Feature | Focal HIFU | Whole-Gland HIFU |
|---|---|---|
| Cancer distribution | Unilateral, MRI-visible, targeted-biopsy confirmed | Bilateral or multifocal disease; or cancer not precisely localizable |
| Gleason / Grade Group | Grade Group 2–3 (GS 3+4 / 4+3) — preferred | Grade Group 2–4 — low, intermediate, and selected high-risk |
| PSA at treatment | Typically <15 ng/mL | Typically <20 ng/mL; higher PSA may indicate need for combined approach |
| Urinary incontinence risk | 2–5% — very low; sphincter and urethra largely spared | 5–10% — higher than focal but still substantially better than surgery |
| Erectile function risk | 65–75% preservation (ipsilateral NVB preserved) | 40–60% preservation — both NVBs at risk from whole-gland thermal effect |
| Post-treatment surveillance | Active surveillance of untreated gland required — MRI + biopsy at 12 months | PSA monitoring alone sufficient — no residual untreated tissue |
| Re-treatment if needed | Residual or contralateral recurrence can be retreated with focal HIFU or radiotherapy | Salvage radiotherapy, focal HIFU to recurrence zone, or systemic therapy |
| Best for | Quality-of-life-focused patients with well-localized cancer willing to accept follow-up | Patients preferring complete treatment with less surveillance burden |
Clinical Outcomes: HIFU vs Surgery and Radiotherapy
The following data compare HIFU outcomes to radical prostatectomy and external beam radiotherapy across cancer control and quality-of-life endpoints for localised prostate cancer.
5-Year Biochemical Recurrence-Free Survival — Low-Intermediate Risk PCa
HIFU: Ablatherm and Sonablate registry data (Crouzet et al.); RP and EBRT: population registry comparators
- Whole-Gland HIFU83%
- Radical Prostatectomy87%
- External Beam Radiotherapy (EBRT)85%
Quality of Life: Pad-Free Urinary Continence at 12 Months
Focal HIFU: Guillaumier et al. (UCL); RP: LHRH trial comparative data; values approximate
- Focal HIFU97%
- Whole-Gland HIFU90%
- Nerve-Sparing Radical Prostatectomy78%
The Prostate HIFU Procedure: What Happens
Prostate HIFU is performed under spinal or general anaesthesia and typically completed in 1–3 hours as a day-case or overnight procedure.
- 1
Pre-Procedure Bowel Preparation
An enema is administered the evening before and the morning of the procedure to empty the rectum — the acoustic path for the transrectal HIFU probe.
- 2
Anaesthesia
Spinal anaesthesia (most common in China and Europe) or general anaesthesia. A urinary catheter is inserted under anaesthesia.
- 3
Transrectal Probe Insertion
A water-cooled transrectal HIFU transducer (Ablatherm or Sonablate) is inserted into the rectum and positioned against the posterior prostate wall. The rectal wall is continuously cooled to prevent thermal injury.
- 4
Imaging and Treatment Planning
Pre-treatment transrectal ultrasound maps the prostate dimensions, identifies the cancer zone (for focal HIFU), and defines treatment boundaries at the bladder neck and apex.
- 5
HIFU Ablation
Systematic focal delivery proceeds from the apex toward the base, slice by slice. For focal HIFU, only the pre-defined cancer-bearing zone is treated. For whole-gland, the entire prostate is ablated. The rectal wall temperature is monitored continuously and cooling activated if thresholds are approached.
- 6
Catheter and Recovery
The urinary catheter remains in place for 7–14 days post-procedure while the ablated prostate tissue swells then subsides. Most patients are discharged the same day or the following morning.
More from the HIFU Therapy Resource Library
Continue exploring HIFU — from how it works to uterine fibroid, liver, and bone applications.
Frequently Asked Questions
Common questions from men considering HIFU for localised prostate cancer.
About Prostate HIFU
Is prostate HIFU a good option after an active surveillance period?
Yes — men whose disease progresses on active surveillance to Grade Group 2–3 are a core indication for focal HIFU. The advantage of intervening at this stage is that disease is typically still unilateral and MRI-localizable, making focal HIFU — with its superior continence and potency preservation profile — the ideal curative intervention. Patients who have been on active surveillance already appreciate the minimal disruption HIFU represents compared to surgery or radiotherapy.
What happens to my PSA after prostate HIFU?
After whole-gland HIFU, PSA should fall to a nadir below 0.5 ng/mL (most definitions use 1.0 ng/mL as the threshold) within 3–6 months — reflecting successful ablation of all PSA-producing prostatic tissue. After focal HIFU, PSA reduction is partial — the untreated lobe continues to produce PSA — so standard biochemical failure definitions for whole-gland treatment do not apply. Your treating team will define specific PSA monitoring targets appropriate to your treatment volume and pre-treatment baseline.
Can I receive HIFU if I previously had radiotherapy for prostate cancer?
Salvage HIFU after radiotherapy failure is a recognised indication — and one where HIFU has a particularly important role, because surgical salvage prostatectomy after radiation carries very high complication rates. Post-radiation tissue is fibrosed and fragile — HIFU can ablate recurrent cancer in the previously irradiated prostate without the bleeding and anastomotic complication risks of salvage surgery. Salvage HIFU series report cancer control rates of 50–60% at 5 years with acceptable toxicity. This should be performed at a centre with specific experience in the post-radiation setting.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Explore HIFU for Your Prostate Cancer Case
CancerFax reviews your PSA history, biopsy Gleason grade, MRI staging, and prior treatment history to assess whether focal or whole-gland HIFU is appropriate — and connects you with experienced urological oncologists at Chinese HIFU centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.